>
Floating Energy Assets Explained
What if Iran's next move against Washington is not a missile launch, but a convoy of oil tankers
Artificial Intelligence Could Transform Bank Runs From Hours-Long Crises...
Dubai Just Finished the World's First Permanent Air Taxi Route: Airport to the Marina in Under 1
Doroni Aerospace Raises More than $60m for H1?X Development
After 13 Years Battling Cancer, a 61-Year-Old Brazilian Man Achieved Complete Remission...
Extraterrestrial habitats may rise via Legos of laser-fused moon dust
Battery-only 19-seater puts China in the electric airliner race
Dream Chaser space plane gets landing approval for debut mission in 2027
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever

The one-two punch provided by the novel approach could pave the way for earlier detection and more effective treatment of the disease.
With an average five-year survival rate of less than 10%, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer. It's also difficult to detect using conventional imaging methods, including positron emission tomography (PET) scans.
Now, researchers at Osaka University in Japan have developed a strategy for combatting this deadly cancer by combining therapeutics and diagnostics – 'theranostics' – into a single, integrated process.
The process developed by the researchers uses radioactive monoclonal antibodies (mAb) to target glypican-1 (GPC1), a protein highly expressed in PDAC tumors. GPC1 has been implicated in cancer cell proliferation, invasion, and metastasis, and high expression of the protein is a poor prognostic factor in some cancers, including pancreatic cancer.
"We decided to target GPC1 because it is overexpressed in PDAC but is only present in low levels in normal tissues," said Tadashi Watabe, the study's lead author.
The researchers injected human pancreatic cancer cells into mice, allowing them to develop into a full tumor. The xenograft mice were administered intravenous GPC1 mAb labeled with radioactive zirconium (89Zr) and observed for antitumor effects.
"We monitored 89Zr-GPC1 mAb internalization over seven days with PET scanning," said Kazuya Kabayama, the study's second author. "There was strong uptake of the mAb into the tumors, suggesting that this method could support tumor visualization. We confirmed that this was mediated by its binding to GPC1, as the xenograft model that had GPC1 expression knocked out showed significantly less uptake."